Weekly Skin Scan

Welcome to The Weekly Skin Scan where our editors will keep you up-to-date on the latest news and research that could impact your practice. Browse more stories here.

Covid-19 Update

Video: The immunocompromised dermatology patient and COVID-19

In light of the ongoing pandemic, Vivian Shi, M.D., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.

Filling PPE gaps one visor at a time

Bluestone Sunshields is helping fill the gaps of PPE available to those working on the frontlines of the COVID-19 pandemic by converting their UV ray-blocking visors into clear face shields.

Acne and Rosacea

Acne pipeline holds promise

“We have not seen a new product line and a pipeline like this in a very long time. We have a toolbox now that is amazing, and in my opinion, many of these new drugs are really going to change the way in which we treat acne," says Hilary E. Baldwin, M.D.

Rosacea: Target the mast cell

It is likely indisputable that better understanding of rosacea etiology could offer new targets for developing better treatments, says Guy F. Webster, M.D., Ph.D., who proposes a focus on controlling mast cell activity.

Psoriasis and Atopic Dermatitis

Topical guidelines will provide real-world guidance

The latest set of guidelines for psoriasis being developed by the American Academy of Dermatology and the National Psoriasis Foundation will stress patient education and the need to align treatment strategies with patient lifestyles.

Ruxolitinib data positive for efficacy, safety

Ruxolitinib met primary and secondary endpoints in the phase 3 TRueE-AD1 and TRuE-AD2 studies, underscoring the idea that the disruption of multiple cytokine networks simultaneously is a promising treatment approach.

Skin Cancer

App has potential to improve adolescent sun protection behavior

A recently published study in JAMA Dermatology showcases positive results for a face aging app’s effect on adolescent skin cancer protection behavior.

Connect with us on Twitter and Facebook for daily updates.

From our Latest Issue

Immunotherapy for advanced squamous cell carcinoma

Soliton’s Generation II tattoo-removal device receives 510(k) premarket notification

Molecular study highlights drug differences in atopic dermatitis